Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Samsung Bioepis

- PMLiVE

Merck & Co’s Remicade biosimilar undercuts its US rivals

Its version will be 35% cheaper than J&J's originator product

- PMLiVE

Biogen develops quantum computing-based app to speed drug discovery

Collaborates with Accenture and 1QBit in neurological diseases

- PMLiVE

Samsung Bioepis wins CHMP nod for second Humira biosimilar

In addition to Imraldi the regulatory advisors also backed new medicines from AbbVie and Gilead

Biogen Idec building

Biogen wins European spinal muscular atrophy first

Spinraza wins accelerated approval to treat patients with the most common form of SMA

- PMLiVE

Biogen spin-out makes first acquisition

Bioverativ attains rare disease group True North

Biogen Idec building

Biogen hands out $120m upfront for Remedy stroke drug

Cirara vying to be first new treatment since the 1990s

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

Biogen Idec building

NICE backtracks on Biogen’s multiple sclerosis drug Zinbryta

Recommends the treatment after new cost effectiveness and a discount provided

- PMLiVE

Merck BACE inhibitor adds to litany of Alzheimer’s trial failures

Interim data shows “virtually no chance” of clinical success for verubecestat

- PMLiVE

Biotech leaders slam Trump over immigration order

Former Teva CEO Jeremy Levin heads open letter expressing “deep concern and opposition”

Biogen Idec building

Biogen completes haemophilia business separation

Spin-out Bioverativ launched to focus exclusively on rare blood disorders

Biogen Idec building

Biogen proffers new data to support high-priced Spinraza

Trial demonstrates statistically-significant risk reduction in paediatric SMA for potential blockbuster drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links